Sun Pharmaceutical Industries Ltd - Company Profile
Powered by 
All the data and insights you need on Sun Pharmaceutical Industries Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Sun Pharmaceutical Industries Ltd Strategy Report
- Understand Sun Pharmaceutical Industries Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Sun Pharmaceutical Industries Ltd (Sun Pharma) is a specialty pharmaceutical company that offers an array of pharmaceutical formulations such as branded generics and generic pharmaceuticals. The company’s portfolio includes products for the treatment of psychiatric, neurological, nephrological, gastroenterological, orthopedic and ophthalmologic diseases and disorders, and heart diseases. The company carries out product development, process chemistry, and manufacture of complex formulations, active pharmaceutical ingredients (APIs) and over-the-counter products. It offers drugs in various dosage forms such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company has manufacturing facilities in North America, Latin America, EMEA and Asia Pacific. Sun Pharma is headquartered in Mumbai, Maharashtra, India.
Headquarters
India
Address
Sun House, Cts No. 201 B/1, Western Exp, Mumbai, Maharashtra, 400093
Website
sunpharma.com
Telephone
91 22 43244324
No of Employees
41,000
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SUNPHARMA (NSE)
Revenue (2022)
$5.6B
13.5%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
158.9%
(2022 vs 2021)
Market Cap*
$44.4B
Net Profit Margin (2022)
XYZ
128.0%
(2022 vs 2021)
* As of and is in US$
Sun Pharmaceutical Industries Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Product Categories: | Amixide |
| Formulations | Alzolam-Sr |
| Active Pharmaceutical Ingredients | Amlosun |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Product Recall | In March, the company recalled about 55,000 bottles of generic medication from the American market because of manufacturing practices norms deviations. |
| 2024 | Plans/Strategy | In February, the company announced its plans to acquire a 16.33% stake in Surgimatix, Inc. |
| 2024 | Plans/Strategy | In January, the company announced its plans to acquire all the shares of Taro Pharmaceutical Industries. |
Competitor Comparison
| Key Parameters | Sun Pharmaceutical Industries Ltd | Pfizer Inc | Sanofi | Novartis AG | Fresenius SE & Co KGaA |
|---|---|---|---|---|---|
| Headquarters | India | United States of America | France | Switzerland | Germany |
| City | Mumbai | New York | Paris | Basel | Bad Homburg |
| State/Province | Maharashtra | New York | Ile-de-France | - | Hessen |
| No. of Employees | 41,000 | 88,000 | 87,994 | 76,057 | 193,865 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Dilip S. Shanghvi | Director; Managing Director | Executive Board | 2012 | 67 |
| C. S. Muralidharan | Chief Financial Officer | Senior Management | 2017 | - |
| Anil Rao | Senior Vice President; Chief Information Officer | Senior Management | 2022 | - |
| Suresh Kumar Rai | Chief Human Resources Officer; Senior Vice President | Senior Management | 2023 | - |
| Aalok D. Shanghvi | Executive Vice President - Emerging Markets, Global generic R&D, Global BD (Generics Segment) & API; Director | Executive Board | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward